Current and historical daily PE Ratio for Histogen Inc (
FRA:CPH
) from 2020 to Jun 14 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Histogen stock (FRA:CPH) PE ratio as of Jun 14 2024 is 0.
More Details
Histogen Inc (FRA:CPH) PE Ratio (TTM) Chart
Histogen Inc (FRA:CPH) PE Ratio (TTM) Historical Data
View and export this data going back to 2020. Start your Free Trial
Total 861
- 1
- 2
- 3
- 4
- 5
- 6
- 10
| Histogen PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-06-15 | At Loss | 2023-08-11 | At Loss |
| 2023-10-13 | At Loss | 2023-08-10 | At Loss |
| 2023-10-12 | At Loss | 2023-08-09 | At Loss |
| 2023-10-11 | At Loss | 2023-08-08 | At Loss |
| 2023-10-10 | At Loss | 2023-08-07 | At Loss |
| 2023-10-09 | At Loss | 2023-08-04 | At Loss |
| 2023-10-06 | At Loss | 2023-08-03 | At Loss |
| 2023-10-05 | At Loss | 2023-08-02 | At Loss |
| 2023-10-04 | At Loss | 2023-08-01 | At Loss |
| 2023-10-03 | At Loss | 2023-07-31 | At Loss |
| 2023-10-02 | At Loss | 2023-07-28 | At Loss |
| 2023-09-29 | At Loss | 2023-07-27 | At Loss |
| 2023-09-28 | At Loss | 2023-07-26 | At Loss |
| 2023-09-27 | At Loss | 2023-07-25 | At Loss |
| 2023-09-26 | At Loss | 2023-07-24 | At Loss |
| 2023-09-25 | At Loss | 2023-07-21 | At Loss |
| 2023-09-22 | At Loss | 2023-07-20 | At Loss |
| 2023-09-21 | At Loss | 2023-07-19 | At Loss |
| 2023-09-20 | At Loss | 2023-07-18 | At Loss |
| 2023-09-19 | At Loss | 2023-07-17 | At Loss |
| 2023-09-18 | At Loss | 2023-07-14 | At Loss |
| 2023-09-15 | At Loss | 2023-07-13 | At Loss |
| 2023-09-14 | At Loss | 2023-07-12 | At Loss |
| 2023-09-13 | At Loss | 2023-07-11 | At Loss |
| 2023-09-12 | At Loss | 2023-07-10 | At Loss |
| 2023-09-11 | At Loss | 2023-07-07 | At Loss |
| 2023-09-08 | At Loss | 2023-07-06 | At Loss |
| 2023-09-07 | At Loss | 2023-07-05 | At Loss |
| 2023-09-06 | At Loss | 2023-07-04 | At Loss |
| 2023-09-05 | At Loss | 2023-07-03 | At Loss |
| 2023-09-04 | At Loss | 2023-06-30 | At Loss |
| 2023-09-01 | At Loss | 2023-06-29 | At Loss |
| 2023-08-31 | At Loss | 2023-06-28 | At Loss |
| 2023-08-30 | At Loss | 2023-06-27 | At Loss |
| 2023-08-29 | At Loss | 2023-06-26 | At Loss |
| 2023-08-28 | At Loss | 2023-06-23 | At Loss |
| 2023-08-25 | At Loss | 2023-06-22 | At Loss |
| 2023-08-24 | At Loss | 2023-06-21 | At Loss |
| 2023-08-22 | At Loss | 2023-06-20 | At Loss |
| 2023-08-21 | At Loss | 2023-06-19 | At Loss |
| 2023-08-18 | At Loss | 2023-06-16 | At Loss |
| 2023-08-17 | At Loss | 2023-06-15 | At Loss |
| 2023-08-16 | At Loss | 2023-06-14 | At Loss |
| 2023-08-15 | At Loss | 2023-06-13 | At Loss |
| 2023-08-14 | At Loss | 2023-06-12 | At Loss |
Histogen Inc (FRA:CPH) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Histogen Inc
NAICS : 541714
SIC : 2833
ISIN : US43358Y2028
Description
Histogen Inc is a clinical-stage therapeutics company focused on developing proprietary hypoxia-generated growth factor technology platforms and stem cell-free biologic products as potential first-in-class restorative therapeutics that ignite the body's natural process to repair and maintain healthy biological function. Under its biologics technology platform, the product candidates in development are HST-003, a treatment for joint cartilage repair, and HST-004, a treatment for spinal disc repair. It also has a pipeline of clinical and preclinical small molecule pan-caspase and caspase selective inhibitors focused on treatments for infectious and inflammatory diseases that the company intends to develop.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers